Drugs / SNSP113
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03309358 | Sep → Dec 2017 | Pseudomonas infection, cepacia syndrome, cystic fibrosis, pulmonary non-tuberculous mycobacterial infection | Synspira, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNSP113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03309358 ↗ |
| Route | Inhaled | “A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.” NCT03309358 ↗ |